Executive Appointment Puts Customer Experience in Focus
Kestra Medical Technologies (KMTS) has created a new senior leadership role and appointed Curtis Kopf as Senior Vice President of Customer Experience, placing renewed attention on how patients and providers interact with the ASSURE wearable cardioverter defibrillator.
At a share price of $25.54, Kestra Medical Technologies has seen a 28.21% 90 day share price return and a 43.00% 1 year total shareholder return. This suggests momentum has been building even as recent earnings expectations have softened and the new customer experience hire adds another talking point ahead of the September 14 results.
Scan how other healthcare stocks with strong balance sheets and fundamentals are reacting to similar leadership and earnings narratives through our curated list of solid balance sheet and fundamentals (53 results) for comparison.
After a 43.00% 1 year total shareholder return and with earnings estimates moving lower ahead of September 14, the question for Kestra Medical Technologies now is whether to accept today’s price or wait for a cheaper entry.
Most Popular Narrative: 20.2% Undervalued
Against the last close of $25.54, the most followed narrative for Kestra Medical Technologies points to a fair value of $32.00. The new customer experience focus sits on top of a story already built around growth and future earnings potential.
The assumed bullish price target for Kestra Medical Technologies is $32.0, which represents up to two standard deviations above the consensus price target of $28.43. This valuation is based on what can be assumed as the expectations of Kestra Medical Technologies’s future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
Want to see what backs that higher fair value for Kestra Medical Technologies? The narrative leans on rapid revenue expansion, margin uplift and a rich future earnings multiple. Curious which specific growth and profitability assumptions have to line up to support that $32 mark?
Result: Fair Value of $32 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, Kestra Medical Technologies still carries clear risks, including ongoing net losses and reliance on wider wearable cardioverter defibrillator adoption that may not materialise as analysts expect.
Find out about the key risks to this Kestra Medical Technologies narrative.
Another View on Kestra Medical Technologies’ Valuation
The bullish fair value of $32 for Kestra Medical Technologies leans heavily on future growth and margin improvement. Yet the stock trades on a P/S ratio of 15.7x, compared with 3x for the US Medical Equipment industry and a fair ratio of 4x. This points to a rich pricing set up that could compress if expectations change.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With both risks and rewards in play around Kestra Medical Technologies, it helps to look past the headlines and test the numbers yourself. To weigh those cross currents quickly and decide where you stand, review the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Kestra Medical Technologies?
If Kestra Medical Technologies is on the watchlist, do not stop there. Spread your research across other strong setups so you are not relying on a single story.
Use the Simply Wall St screener to quickly surface complementary ideas that fit different risk and income profiles. These shortlists help you compare opportunities side by side and see where Kestra Medical Technologies fits in your broader plan.
- Spot potential value opportunities early by reviewing companies that pass the 47 high quality undervalued stocks and decide which ones deserve a closer look before attention broadens.
- Strengthen the quality of your watchlist by scanning stocks in the 80 resilient stocks with low risk scores that may offer a smoother ride when markets turn choppy.
- Give your income portfolio fresh options by checking out the 11 dividend fortresses and see which high yield plays might complement your existing holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Kestra Medical Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
Robinhood now earns more from people betting on outcomes than companies. Is that a flaw or a feature?
Q2 had the World cup. Not a signal. Robinhood has hardly moved this year.
Contrarian take: Gambling can only expand as much. If you are keeping a close eye in the image represented here, crypto volumes have shifted to events.
Mitchell Lawler
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picks
Fresh 13F filings are where some investors go to find their next stock pick. The problem is it’s missing some of the most important details for making a good investment.
62
Sep 4, 2026
About NasdaqGS:KMTS
Kestra Medical Technologies
Operates as a wearable medical device and digital healthcare company.
Flawless balance sheet with limited growth.
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picksMI
Mitchell Lawler
Great earnings season, but are the earnings real?AN
Andrew Legget
Which payment stocks actually get paid?MI
Mitchell Lawler
Advertisement
Weekly Picks
Lou_Baseneseon Oncolytics Biotech·20 days ago
The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech
Fair Value:US$3.575.9% undervalued
68followersusers have followed this narrative
·1commentusers have commented on this narrative
·18likesusers have liked this narrative
AN
andrei9868on ServiceNow·24 days ago
The Platform Turning Enterprise Chaos into Autonomous Workflows
John_Ericon Vistra·8 days ago
Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here’s the $472 Million Reason They Disagree.
Fair Value:US$291.8748.8% undervalued
52followersusers have followed this narrative
·2commentsusers have commented on this narrative
·20likesusers have liked this narrative
HA
HarishPKon EverQuote·18 days ago
EverQuote and an Asymmetric Investment Opportunity
RecentlyUpdated Narratives
Alhabibon Zevra Therapeutics·21 minutes ago
revenue is growing while new-patient acquisition has decelerated sharply
John_Ericon IREN·about 6 hours ago
The Bitcoin Miner Who Accidentally Built the Best Real Estate Portfolio in AI
RockeTelleron West Red Lake Gold Mines·about 13 hours ago
This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold
Popular Narratives
AnalystConsensusTargeton NVIDIA·about 1 month ago
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$302.8323.9% undervalued
1382followersusers have followed this narrative
·8commentsusers have commented on this narrative
·35likesusers have liked this narrative
OSoscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
John_Ericon MercadoLibre·3 days ago
